DOTATATE PET for Meningioma Radiation Planning

ConditionMeningioma
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBritish Columbia Cancer Agency

About this trial

68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET

Eligibility criteria

Qualifiers

Age ≥ 18 years old

Able and willing to comply with the study procedures

Intact meningioma requiring definitive radiation

Post-operative meningioma requiring adjuvant radiation

Disqualifiers

Breastfeeding or pregnancy

Claustrophobia or inability to lie still in a supine position

Unwillingness or inability to provide informed consent

Trial design

Treatments tested in this trial

  • DOTATATE-PET scan

Treatment groups

36 Participants
are divided into 1 treatment group

Sponsors and collaborators